Presentations by Dr. Alexandra Graham, Phytosearch and BDA Foundation/PharmAfrican made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...Pharm Net
The document discusses the global impact of hepatitis C treatment drugs launched by pharmaceutical companies. It provides information on hepatitis C, including key facts about transmission and prevalence in different countries. It analyzes the hepatitis C treatment market globally and regionally, including major players and drug classes. It also discusses the response of different countries like Pakistan, Indonesia, and India to changes in hepatitis C treatment guidelines and availability of generic drugs.
East African Pharmaceutical Sector: Opportunities and ChallengesPharmaAfrica
Presentation by Nazeem Mohamed, Federation of East African Pharmaceutical Manufacturers made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Presentation by Adil Zanfari, President, Genpharma, Morocco made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Arvind ltd@ organic staple business mts 01 presentationanjaney
This document presents a market research study conducted for Arvind Company Ltd. on the potential for organic staple crops in domestic and global markets. The study analyzed Arvind's organic farming project in Akola, Maharashtra, which works with over 3,500 farmers. It found the project produces a variety of organic staple crops across different seasons. The study's objectives were to estimate production potential, review domestic and global organic markets, and develop a marketing strategy. It proposed strategies for domestic distribution through retailers and export to countries like the EU and US, which have growing organic markets. The conclusion was that organic farming provides benefits and the business could be profitable if low costs and quality standards are maintained.
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...Pharm Net
The document discusses the global impact of hepatitis C treatment drugs launched by pharmaceutical companies. It provides information on hepatitis C, including key facts about transmission and prevalence in different countries. It analyzes the hepatitis C treatment market globally and regionally, including major players and drug classes. It also discusses the response of different countries like Pakistan, Indonesia, and India to changes in hepatitis C treatment guidelines and availability of generic drugs.
East African Pharmaceutical Sector: Opportunities and ChallengesPharmaAfrica
Presentation by Nazeem Mohamed, Federation of East African Pharmaceutical Manufacturers made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Presentation by Adil Zanfari, President, Genpharma, Morocco made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Arvind ltd@ organic staple business mts 01 presentationanjaney
This document presents a market research study conducted for Arvind Company Ltd. on the potential for organic staple crops in domestic and global markets. The study analyzed Arvind's organic farming project in Akola, Maharashtra, which works with over 3,500 farmers. It found the project produces a variety of organic staple crops across different seasons. The study's objectives were to estimate production potential, review domestic and global organic markets, and develop a marketing strategy. It proposed strategies for domestic distribution through retailers and export to countries like the EU and US, which have growing organic markets. The conclusion was that organic farming provides benefits and the business could be profitable if low costs and quality standards are maintained.
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREADPinky Fadullon
This document provides information about the 6th Annual Global Orphan Drug Conference and Expo taking place April 21-22, 2016 in Washington D.C. The conference will bring together stakeholders in the orphan drug industry including pharmaceutical companies, patient advocacy groups, regulators, payers, and investors. It will include keynote sessions, workshops on topics like market forecasting and commercialization, and networking opportunities. A pre-conference day of workshops is scheduled for April 20th.
The document discusses how CGIAR is applying a One Health approach to address COVID-19 and prevent future pandemics through agricultural research. CGIAR is conducting research to understand disease drivers, improve diagnostics and surveillance, strengthen biosecurity, and promote cross-sector collaboration. This includes ILRI repurposing its lab to process COVID-19 tests in Kenya and advising Ethiopia on testing strategies. A One Health approach that considers the interactions between human, animal and environmental health could help reduce disease emergence and save billions by limiting future pandemics according to economic analyses.
Introduction to the SBRI Competition: Vaccines for Epidemic DiseasesKTN
This document provides information about an upcoming SBRI (Small Business Research Initiative) competition focused on vaccines for epidemic diseases. It summarizes the agenda for an information session on the competition, including welcome remarks, an overview of the UK Vaccine Network and competition aims, and details about the call and timelines. The competition will provide up to £10 million in funding across multiple projects to enhance clinical and regulatory preparedness of vaccines for UKVN priority pathogens or "Disease X". Applications will be accepted from October 11-November 10, 2021 and contracts are expected to be awarded starting April 1, 2022.
Webinar 1 (Oct 9, 2020 at 12 -1 pm ET): Does Canada need an Orphan Drug Policy to incentivize drug development and submissions? What was the rationale for Orphan Drug legislation in other countries? What has been the impact of those legislations? Why did Canada develop and never implement a Canadian Rare Disease Strategy and what has been the aftermath? What is Canada’s Rare Disease Strategy and how has it influenced healthcare?
Key issues:
• Rationale and impact of Orphan Drug legislation around the world (1983 – today)
• Proposed Canadian Orphan Drug Framework and what could have resulted (2014)
• Proposed Canada’s Rare Disease Strategy and what did/did not result (2015 – today)
Given the benefits and challenges that have been raised about Orphan Drug Legislation and the current procedures for reviewing rare disease drugs across Canadian agencies (Health Canada, PMPRB, CADTH/INESSS, pCPA, provincial drug plans), should Canada still pursue a dedicated Orphan Drug Policy and, if so, what should it address? What are the opportunities for stimulating and supporting research and development for rare disease therapies in Canada and what are specific policies needed?
Presentation:
Durhane Wong-Rieger, CORD Panel Discussion
Rebecca Yu (Takeda Canada)
Nicola Worsfold (Jesse’s Journey Canada)
Sandra Anderson (Innomar Strategies)
Nahya Awada (PhD Candidate Carleton University)
This slide show provides an overview of the market for pain resolution in Germany and UK, the Company's plan for entering the market in Germany and the UK.
The COVID-19 vaccine race is progressing rapidly, with a handful of candidates already entering Phase 3 clinical trials in Q3 2020. Deals are being struck between developed nations and the top vaccine developers to secure doses even before FDA approval. Coalitions & alliances are also being set up to ensure vaccine access for lower-income countries.
Virginia Llera - Cómo optimizar la investigación en Enfermedades RarasFundación Ramón Areces
La Doctora Virginia Llera, Virginia A. Llera ofreció una conferencia el 17/09/2014 en la Fundación Ramón Areces. Llera es la Fundadora de la primera organización de Enfermedades Raras y drogas huérfanas en Latino América y Caribe, GEISER, y Presidenta del Foro Internacional, ICORD (International Conference on Rare Diseases & Orphan Drugs). Su conferencia, titulada 'Optimizando los procesos de investigación en enfermedades raras y medicamentos huérfanos', tuvo lugar dentro del ciclo sobre patologías poco frecuentes organizado por Fundación Ramón Areces en colaboración con Vall d'Hebron Institute of Research, Barcelona.
Virgil H. Simons presented on developing a global platform for prostate cancer advocacy. He discussed the disparities in prostate cancer incidence and outcomes around the world. While spending on prostate cancer treatment is increasing, barriers remain to implementing precision medicine and equitable research. There are also deficits in communication between patients and providers. Simons proposes engaging communities to conduct appropriate research and creating advocacy networks to influence policies that result in comprehensive cancer control programs. The goal is to achieve sustainable and equitable access to healthcare.
The document summarizes initiatives to combat counterfeit medicines in various countries. It finds that healthcare professionals' roles are often unclear and they are not always at the forefront of counterfeiting issues. The WHPA campaign aims to strengthen advocacy for investing in healthcare professionals' education and capacity to detect, report, and prevent counterfeits. It establishes dialogue between stakeholders to share knowledge and resources and initiate cost-effective solutions. The WHPA Call to Action and toolkit provide strategies and resources to build comprehensive regional plans against counterfeiting through increasing professional capacity, regional cooperation, collaborative practice, and improved collaboration with authorities.
Patent Pooling and the Experience of the MPP – A model for sharing the value of innovation to ensure access
MPP's ED Greg Perry's presentation at IFPMA event on January 29, 2014.
Ms. Connie Lau discusses food additives from the consumer's perspective. She summarizes tests conducted by the Hong Kong Consumer Council that found various food additives, like sulphur dioxide and benzoic acid, in dried fruits and vegetarian foods at varying concentrations that were not fully disclosed on labels. This lack of information causes ignorance among consumers about what they are eating. She advocates for providing more information to consumers in accordance with UN Guidelines for Consumer Protection to address ignorance and allay fears. While food additives are controversial, consumers accept their necessity but want representation in decision making to have their voices heard on food safety issues.
Who expert committee recommendations for pharmaceutical productsswati2084
The document summarizes the 43rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. It discusses WHO's work with other international organizations to harmonize pharmaceutical standards and guidelines. It provides updates on ongoing initiatives to improve access to quality medicines, including for priority diseases and children. Key areas of focus are ensuring safety and efficacy of medicines through good manufacturing practices, international reference standards, prequalification programs, and combating counterfeit drugs.
Shock tactics - a reputation minefield or a risk worth taking?CharityComms
The document discusses a shock advertising campaign by the small charity Pancreatic Cancer Action to raise awareness of pancreatic cancer symptoms and diagnosis. The campaign used provocative images and stories of patients to garner media attention. It was successful in significantly increasing awareness of pancreatic cancer and the charity's website traffic and donations, but required careful management of complaints. Overall, the campaign achieved its goal of bringing attention to the important issue of pancreatic cancer diagnosis and survival.
OxfordSM's pharma case studies - providing a call to actionOxfordSM
Brand teams have to be increasingly innovative when finding ways to prompt patients and physicians to intervene at the right time.
Campaigns such as GSK’s Greatest Season Ever for FLONASE®, implemented last year in the United States which made the decision to prepare for the allergy season easier for patients by linking the proactive purchase of the brand to the start of the baseball season.
Providing A Call To Action:
We find that examples from within and outside of healthcare can often prompt this innovation. They act as a way of bringing in new perspectives and allowing teams to explore new avenues and new ideas.
So, in the spirit of hoping this will prompt some new ideas in your brand team, here are our favourite case studies that speak to the need to provide a call to action.
This document lists sponsors, exhibitors, and speakers for the Orphan Drugs & Rare Diseases Global Congress 2016 Europe conference. It provides an overview of the conference agenda which will focus on key issues impacting the orphan drugs industry such as commercialization, policies, reimbursement, pricing, and more. The two-day conference will provide networking and discussion opportunities between representatives from orphan drug manufacturers, big pharmaceutical companies, biopharmaceuticals, governments, patient groups, and others.
This document discusses orphan drugs, which are medications developed to treat rare diseases affecting small patient populations. It provides background on orphan drug regulations in the US and other countries, including incentives established by the Orphan Drug Act of 1983 in the US to encourage development of these drugs. The document also summarizes recent orphan drug approvals by the FDA, and provides market data showing the orphan drug market is growing significantly and expected to reach $355 billion by 2030. It concludes that developing orphan drugs faces unique challenges but is important for treating rare disease patients.
Dr. Chase Crawford - Actions and Recommendations on Antibiotics from the Univ...John Blue
Actions and Recommendations on Antibiotics from the Universities (APLU) and Colleges of Veterinary Medicine (AAVMC) - Dr. Chase Crawford, Director, Antimicrobial Resistance Initiative, Association of American Veterinary Medical Colleges; Association of Public & Land-grant Universities, from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
SPHS Webinar: Ensuring Fair Play in the Global Health Supply Chains UN SPHS
This first United Nations informal Inter Agency Task Team webinar on Sustainable Procurement in the Health Sector (SPHS) is relevant to all those active in the healthcare supply chain - from producers to purchasers. In particular, it is aimed at assisting procurement teams planning to institute sustainability initiatives to think through how they can include a wide diversity of suppliers in these sustainability initiatives. It explains the benefits of ensuring actions which are inclusive of all, allowing small and medium enterprises to meet new standards. It also covers supplier development and how procuring entities can engage with suppliers and manufacturers to understand the challenges they face and how they can work jointly to identify opportunities to integrate sustainability in the supply chain.
Target Market - A continent rich in prospects and enthusiasm, Africa could ha...PharmaAfrica
European Biopharmaceutical Review talks to PharmaAfrica about the vibrant and wide-ranging opportunities on offer for pharma companies looking to expand into new directions. July 2015 edition
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREADPinky Fadullon
This document provides information about the 6th Annual Global Orphan Drug Conference and Expo taking place April 21-22, 2016 in Washington D.C. The conference will bring together stakeholders in the orphan drug industry including pharmaceutical companies, patient advocacy groups, regulators, payers, and investors. It will include keynote sessions, workshops on topics like market forecasting and commercialization, and networking opportunities. A pre-conference day of workshops is scheduled for April 20th.
The document discusses how CGIAR is applying a One Health approach to address COVID-19 and prevent future pandemics through agricultural research. CGIAR is conducting research to understand disease drivers, improve diagnostics and surveillance, strengthen biosecurity, and promote cross-sector collaboration. This includes ILRI repurposing its lab to process COVID-19 tests in Kenya and advising Ethiopia on testing strategies. A One Health approach that considers the interactions between human, animal and environmental health could help reduce disease emergence and save billions by limiting future pandemics according to economic analyses.
Introduction to the SBRI Competition: Vaccines for Epidemic DiseasesKTN
This document provides information about an upcoming SBRI (Small Business Research Initiative) competition focused on vaccines for epidemic diseases. It summarizes the agenda for an information session on the competition, including welcome remarks, an overview of the UK Vaccine Network and competition aims, and details about the call and timelines. The competition will provide up to £10 million in funding across multiple projects to enhance clinical and regulatory preparedness of vaccines for UKVN priority pathogens or "Disease X". Applications will be accepted from October 11-November 10, 2021 and contracts are expected to be awarded starting April 1, 2022.
Webinar 1 (Oct 9, 2020 at 12 -1 pm ET): Does Canada need an Orphan Drug Policy to incentivize drug development and submissions? What was the rationale for Orphan Drug legislation in other countries? What has been the impact of those legislations? Why did Canada develop and never implement a Canadian Rare Disease Strategy and what has been the aftermath? What is Canada’s Rare Disease Strategy and how has it influenced healthcare?
Key issues:
• Rationale and impact of Orphan Drug legislation around the world (1983 – today)
• Proposed Canadian Orphan Drug Framework and what could have resulted (2014)
• Proposed Canada’s Rare Disease Strategy and what did/did not result (2015 – today)
Given the benefits and challenges that have been raised about Orphan Drug Legislation and the current procedures for reviewing rare disease drugs across Canadian agencies (Health Canada, PMPRB, CADTH/INESSS, pCPA, provincial drug plans), should Canada still pursue a dedicated Orphan Drug Policy and, if so, what should it address? What are the opportunities for stimulating and supporting research and development for rare disease therapies in Canada and what are specific policies needed?
Presentation:
Durhane Wong-Rieger, CORD Panel Discussion
Rebecca Yu (Takeda Canada)
Nicola Worsfold (Jesse’s Journey Canada)
Sandra Anderson (Innomar Strategies)
Nahya Awada (PhD Candidate Carleton University)
This slide show provides an overview of the market for pain resolution in Germany and UK, the Company's plan for entering the market in Germany and the UK.
The COVID-19 vaccine race is progressing rapidly, with a handful of candidates already entering Phase 3 clinical trials in Q3 2020. Deals are being struck between developed nations and the top vaccine developers to secure doses even before FDA approval. Coalitions & alliances are also being set up to ensure vaccine access for lower-income countries.
Virginia Llera - Cómo optimizar la investigación en Enfermedades RarasFundación Ramón Areces
La Doctora Virginia Llera, Virginia A. Llera ofreció una conferencia el 17/09/2014 en la Fundación Ramón Areces. Llera es la Fundadora de la primera organización de Enfermedades Raras y drogas huérfanas en Latino América y Caribe, GEISER, y Presidenta del Foro Internacional, ICORD (International Conference on Rare Diseases & Orphan Drugs). Su conferencia, titulada 'Optimizando los procesos de investigación en enfermedades raras y medicamentos huérfanos', tuvo lugar dentro del ciclo sobre patologías poco frecuentes organizado por Fundación Ramón Areces en colaboración con Vall d'Hebron Institute of Research, Barcelona.
Virgil H. Simons presented on developing a global platform for prostate cancer advocacy. He discussed the disparities in prostate cancer incidence and outcomes around the world. While spending on prostate cancer treatment is increasing, barriers remain to implementing precision medicine and equitable research. There are also deficits in communication between patients and providers. Simons proposes engaging communities to conduct appropriate research and creating advocacy networks to influence policies that result in comprehensive cancer control programs. The goal is to achieve sustainable and equitable access to healthcare.
The document summarizes initiatives to combat counterfeit medicines in various countries. It finds that healthcare professionals' roles are often unclear and they are not always at the forefront of counterfeiting issues. The WHPA campaign aims to strengthen advocacy for investing in healthcare professionals' education and capacity to detect, report, and prevent counterfeits. It establishes dialogue between stakeholders to share knowledge and resources and initiate cost-effective solutions. The WHPA Call to Action and toolkit provide strategies and resources to build comprehensive regional plans against counterfeiting through increasing professional capacity, regional cooperation, collaborative practice, and improved collaboration with authorities.
Patent Pooling and the Experience of the MPP – A model for sharing the value of innovation to ensure access
MPP's ED Greg Perry's presentation at IFPMA event on January 29, 2014.
Ms. Connie Lau discusses food additives from the consumer's perspective. She summarizes tests conducted by the Hong Kong Consumer Council that found various food additives, like sulphur dioxide and benzoic acid, in dried fruits and vegetarian foods at varying concentrations that were not fully disclosed on labels. This lack of information causes ignorance among consumers about what they are eating. She advocates for providing more information to consumers in accordance with UN Guidelines for Consumer Protection to address ignorance and allay fears. While food additives are controversial, consumers accept their necessity but want representation in decision making to have their voices heard on food safety issues.
Who expert committee recommendations for pharmaceutical productsswati2084
The document summarizes the 43rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. It discusses WHO's work with other international organizations to harmonize pharmaceutical standards and guidelines. It provides updates on ongoing initiatives to improve access to quality medicines, including for priority diseases and children. Key areas of focus are ensuring safety and efficacy of medicines through good manufacturing practices, international reference standards, prequalification programs, and combating counterfeit drugs.
Shock tactics - a reputation minefield or a risk worth taking?CharityComms
The document discusses a shock advertising campaign by the small charity Pancreatic Cancer Action to raise awareness of pancreatic cancer symptoms and diagnosis. The campaign used provocative images and stories of patients to garner media attention. It was successful in significantly increasing awareness of pancreatic cancer and the charity's website traffic and donations, but required careful management of complaints. Overall, the campaign achieved its goal of bringing attention to the important issue of pancreatic cancer diagnosis and survival.
OxfordSM's pharma case studies - providing a call to actionOxfordSM
Brand teams have to be increasingly innovative when finding ways to prompt patients and physicians to intervene at the right time.
Campaigns such as GSK’s Greatest Season Ever for FLONASE®, implemented last year in the United States which made the decision to prepare for the allergy season easier for patients by linking the proactive purchase of the brand to the start of the baseball season.
Providing A Call To Action:
We find that examples from within and outside of healthcare can often prompt this innovation. They act as a way of bringing in new perspectives and allowing teams to explore new avenues and new ideas.
So, in the spirit of hoping this will prompt some new ideas in your brand team, here are our favourite case studies that speak to the need to provide a call to action.
This document lists sponsors, exhibitors, and speakers for the Orphan Drugs & Rare Diseases Global Congress 2016 Europe conference. It provides an overview of the conference agenda which will focus on key issues impacting the orphan drugs industry such as commercialization, policies, reimbursement, pricing, and more. The two-day conference will provide networking and discussion opportunities between representatives from orphan drug manufacturers, big pharmaceutical companies, biopharmaceuticals, governments, patient groups, and others.
This document discusses orphan drugs, which are medications developed to treat rare diseases affecting small patient populations. It provides background on orphan drug regulations in the US and other countries, including incentives established by the Orphan Drug Act of 1983 in the US to encourage development of these drugs. The document also summarizes recent orphan drug approvals by the FDA, and provides market data showing the orphan drug market is growing significantly and expected to reach $355 billion by 2030. It concludes that developing orphan drugs faces unique challenges but is important for treating rare disease patients.
Dr. Chase Crawford - Actions and Recommendations on Antibiotics from the Univ...John Blue
Actions and Recommendations on Antibiotics from the Universities (APLU) and Colleges of Veterinary Medicine (AAVMC) - Dr. Chase Crawford, Director, Antimicrobial Resistance Initiative, Association of American Veterinary Medical Colleges; Association of Public & Land-grant Universities, from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
SPHS Webinar: Ensuring Fair Play in the Global Health Supply Chains UN SPHS
This first United Nations informal Inter Agency Task Team webinar on Sustainable Procurement in the Health Sector (SPHS) is relevant to all those active in the healthcare supply chain - from producers to purchasers. In particular, it is aimed at assisting procurement teams planning to institute sustainability initiatives to think through how they can include a wide diversity of suppliers in these sustainability initiatives. It explains the benefits of ensuring actions which are inclusive of all, allowing small and medium enterprises to meet new standards. It also covers supplier development and how procuring entities can engage with suppliers and manufacturers to understand the challenges they face and how they can work jointly to identify opportunities to integrate sustainability in the supply chain.
Similar to DEVELOPMENT OF DRUGS FROM INDIGENOUS AFRICAN SOURCES: Partnerships Between North and South (20)
Target Market - A continent rich in prospects and enthusiasm, Africa could ha...PharmaAfrica
European Biopharmaceutical Review talks to PharmaAfrica about the vibrant and wide-ranging opportunities on offer for pharma companies looking to expand into new directions. July 2015 edition
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
Push for greater R&D and innovation in AfricaPharmaAfrica
Presentation by the African Network for Drugs & Diagnostics Innovation made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
The document summarizes the African Medicines Regulatory Harmonisation (AMRH) Initiative. It discusses the background and vision of AMRH, which aims to improve access to essential medicines through regulatory harmonization across Africa. It outlines achievements including establishing an advisory committee and technical working groups, developing a model law, and launching regulatory harmonization projects in several regions. The document also notes industry support for AMRH and how regulatory harmonization can boost healthcare, access to new drugs, and the pharmaceutical industry in Africa over the short and long term. It concludes by highlighting next steps such as expanding the scope of harmonization and establishing sustainable training programs.
Presentation by medicines registration harmonisation in the SADC made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
The document summarizes research into innovative healthcare delivery models around the world. Over 900 programs across 50 countries were identified and screened using a 5-point scale. Six broad model types were found: infrastructure, financing, devices/equipment, social marketing, ICT, and skill training. The top locations for programs were India, Kenya, Uganda and others. Recommendations include engaging with the top 10 programs, using the screening scale to identify others, and developing a long-term strategy to consolidate involvement in innovative models.
Paper presented by GSK's Developing Countries Operating UnitPharmaAfrica
Presentation by GSK's Developing Countries Operating Unit made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
DEVELOPMENT OF DRUGS FROM INDIGENOUS AFRICAN SOURCES: Partnerships Between North and South
1. DEVELOPMENT OF DRUGS FROM
INDIGENOUS AFRICAN SOURCES
Partnerships Between
North and South
Dr. Alexandra E Graham
Vice President, LaGray
President, PhytoSearch
International
2. LaGray, Inc. Mission
We establish state of the art
pharmaceutical manufacturing facilities
in Africa that are compliant with
international standards of GMP;
We develop African indigenous remedies
into quality-assured medicines;
We form partnerships to deliver
healthcare solutions in Africa.
3. LaGray, Inc. Vision
Our vision is to provide lasting
solutions to Africa’s healthcare
problems through sustainable
technological growth that leads
to self-sufficiency
4. LaGray Chemical Company, Ghana
Objective to establish fully vertically
integrated pharmaceutical manufacturing
company in Africa
• Fully GMP Compliant
• Vertically integrated
• Drug discovery and development
capabilities
8. Recognition
“As Ghanaian and Nigerian Americans,
you have a unique ability to help because
of the power of your experience”
- William Jefferson Clinton
(April 2003)
2009 Frost & Sullivan African Excellence award for innovation in
the pharmaceuticals business
2nd Ghana Business & Finance Excellence award, Gold Category
2010
3rd Ghana Business & Finance Excellence Award, Gold Category
2011
ANDI Center of Excellence for Drug Manufacturing 2012
9. Set up for partnerships
Public private partnerships for custom
solutions to pharmaceutical needs in Africa
Custom manufacturing services to other
companies, distributors, NGOs
Partnering for drug discovery from
indigenous natural product resources
10. Phytosearch is a non-profit 501 c (3) corporation
Focused on development of indigenous African
medicinal plants into affordable standardized
medicines with proven:
• Efficacy in specified indications
• Good safety profile
• Assurance of consistent quality
11. Anti-malarial Drug Discovery: Conquests
Spanish colonization
•
1
H
•
1630: Discovery of infusion of bark of
Cinchona sp. For treatment of malaria
Production of Jesuit powder as
wonder drug in aid of colonization
N
French colonization
HO
H 3 CO
5
4
2
8
N
Quinine
•
2
1820: Isolation of quinine from
Cinchona nitida . Availability of
quinine as a drug in quest to colonize
12. Anti-malarial Drug Discovery: World Wars
H
N
Lessons from WWI
HO
H 3 CO
Quinine
5
•
3
4
2
8
N
CH 3
CH 3
H
N
N
OCH
CH 3
3
Quinacrine
Cl
N
1917: German identification of
quinacrine based on quinine
pharmacophore
13. Anti-malarial Drug Discovery: World Wars
H
World War II
N
HO
H 3 CO
5
4
N
CH 3
OH
N
H
•
4
1939: German synthesis of
chloroquine based on quinine
pharmacophore
•
5
Quinine
2
8
1942: American synthesis of
amodiaquine based on
quinine pharmacophore
CH 3
N
Amodiaquinine
Cl
N
CH 3
CH 3
N
H
CH 3
N
Chloroquine
Cl
N
14. Anti-malarial Drug Discovery: Other Wars
H
Vietnam War
HO
N
N
H
HO
5
•
6
4
N
2
8
N
1963: American
synthesis of
mefloquine as
prophylactic against
malaria
•
7
H 3 CO
1970: American
synthesis of
halofantrine – one
day treatment
CF 3
CF 3
Mefloquine
CH 3
CH 3
N
HO
Cl
F 3C
Halofantrine
Cl
15. Anti-malarial Drug Discovery: Other Wars
Artemisia annua
•
8
CH 3
H
O
H 3C
Vietnam War – The other side
O
1971: Chinese isolation of
artemisinin from Artemisia annua to
help their Vietnam allies
O
H
O
CH 3
O
Artemisinin
Combination of artemisinin
derivatives with aminoquinolines
– now standard first line
treatment
18. Cryptolepine
Plant extract – Decoction/tea bag
• Efficacy in malaria comparable
to chloroquine
• 93.5% cure rate
• Antipyretic and
antiinflammatory properties
• No overt toxicity observed
Cryptolepine
• In vitro activity vs. chloroquine
sensitive and resistant
P. falciparum
• MOA: inhibition of heme
detoxification in parasite
• Cytotoxicity
• LD50 mouse
Poor therapeutic index
G.L. Boye, Proc. Int. Symp. On East-West Medicine, 1989, Oct. 10-11, Seoul, S. Korea
K.A. Bugyei, Ghana Med. J., 44, 3 (2010)
19. Approach
• Identify required expertise in Africa and form
partnerships
− Public research institutions
− Private sector expertise
− Government commitment and support
• Seek funding to support public private partnership
• Lead milestone-driven process to develop clinically
proven product
20. Private Sector Partner: Drug Development
Development of standardized
active plant material
Development of standardized formulations
Capsules/Dispersible tablets
Manufacture of clinical
Samples under cGMP
Manufacturing process
development and validation
21. Private and Public Partners: Sustainability
• Cultivars developed from seeds
• Seedlings can be given for farming
• C. sanguinolenta has potential as a cash crop
23. Government of Ghana
Contribution
USD 1 Million for Clinical Trials of Cryptolepis
sanguinolenta capsules by Noguchi Memorial
Institute for Medical Research (NMIMR)
24. Partnerships for Drug Development
Herbal
Medicines
Validated
through
Science
Developed
through
partnership
Research
Institutions
Commercialized
by
Africa-based
Manufacturers
Private
Sector
Government
Support
26. The Medicines Patent Pool
advancing innovation, expanding access, promoting public health
Greg Perry
Executive Director
www.medicinespatentpool.org
27. MPP Created to Expand Access, Increase
Innovation, Promote Health in HIV
• MPP endorsed by the UN General Assembly, the World Health
Organization and the G8
WIN-WIN-WIN
SOLUTION
ONE-STOP
SHOP
• Global treatment gap: Only 54% PLHIV, 28% CLHIV on treatment
• Access to patented products is critical for the lives of millions in
Africa. MPP can make innovation accessible through IP sharing
28. African Context
• 34 million PLHIV. 69% live in Sub-Saharan Africa
• 3.4 million CLHIV. 90% live in Sub-Saharan Africa
• Since 2001, the number of people newly infected in the
Middle East and North Africa increased by more than 35%
• CHALLENGES:
Intellectual Property
Regulation
Price / Purchasing power
29. Three Main Objectives
•
Enable the development of fixed
dose combinations (FDCs) of
which the patents are held by
different entities
•
Enable the development of
adapted formulations for
children or for specific developing
country needs (e.g., heat stable)
•
Accelerate the availability of
generic versions of new ARVs in
developing countries
29
30. Our Licences
Components of our licences:
Transparent
Broad developing country reach
economies of scale
Technology transfer (Gilead)
Data exclusivity waivers
Right of manufacturing globally (ViiV)
Voluntary
31. Impact
•
Five priority ARVs including one paediatric ARV licence in MPP
•
Six ARV manufacturers licensed from MPP, more affordable ARVs
already being purchased in at least 10 developing countries
•
Technology transfer to generic manufacturers carried out in relation to
four ARVs
•
On track to accelerate availability of new ARVs in developing countries
•
Awarded a Deal of Distinction Award by the Licensing Executives
Society
•
Patent Status Database is "an invaluable step towards furthering
access to treatment of HIV/AIDS" by UN agencies and major
organizations procuring ARVs
32. Viiv Licence – Call For Generics
Just announced invitations to sub-licencees for paediatric abacavir.
The two key criteria are:
Demonstrated capability and willingness to develop, manufacture and
distribute ARV paediatric formulations in developing countries
Quality requirements: WHO Prequalification, USFDA, EMA or other
stringent regulatory authority
More information is available on our website
www.medicinespatentpool.org
33. Thank You
“Encouraging the voluntary use, where appropriate, of new mechanisms such as partnerships, tiered
pricing, open-source sharing of patents and patent pools benefiting all developing countries, including
through entities such as the Medicines Patent Pool, to help reduce treatment costs and encourage
development of new HIV treatment formulations, including HIV medicines and point-of-care diagnostics, in
particular for children” – UN General Assembly Political Declaration on HIV/AIDS, June 2011
“The Medicines Patent Pool is a means to enhance availability and facilitate the
development of new fixed-dose combinations and adapted formulations, such as
paediatric formulations, through voluntary licence agreements.” - HIV Strategy
2011-2015
“We welcome the Patent Pool Initiative launched by UNITAID…and we invite the voluntary participation of
patent owners, private and public, in the project.” – G8 Summit, Deauville, France, May 2011
“Encourage the use of new mechanisms such as the UNITAID Medicines Patent Pool to help
reduce treatment costs and promote the development of new treatment
formulations, including paediatric formulations and fixed-dose combinations.” – Sao Paulo
Parliamentary Declaration on Access to Medicines and Other Pharmaceutical
Products, Global Fund Partnership Forum, June 2011
“The Medicines Patent Pool has potential to support access to more appropriate and affordable ARVs in
developing countries by setting incentives for product adaptation and generic production. We will
encourage the pharmaceutical sector to engage actively with the Medicines Patent Pool to support the
availability of more appropriate and affordable ARVs.” – UK Position Paper on HIV, May 2011
"One promising initiative that can help decrease the cost of patents for the Index Countries is
the patent pool initiative of UNITAID.“ - ATM Index 2010
“We urge all public institutions and pharmaceutical companies to follow the measures taken
by the NIH, and to share without delay their patents on this and other antiretrovirals with the
Medicines Patent Pool, in order to facilitate access to these treatments at the lowest possible
price for countries in need.” - Prof. Michel Kazatchkine, Former Executive Director
“This licence underlines the U.S. Government’s commitment to the Medicines Patent Pool and its goal to
increase the availability of HIV medicines in developing countries. We are now discussing licensing to the
Medicines Patent Pool other patents that could have a positive impact on the treatment of HIV/AIDS.”
- NIH Director Francis S. Collins, M.D., Ph.D.
34.
35. Objectives for this session
▪
Medical products in Africa
Present a perspective on the opportunities in the
Continent and the implications for local/global players
▪
Innovation and tech transfer
Discuss what is needed in terms of innovation and
the positioning of local players
▪
Open questions
Openly discuss how access and innovation can be
enhanced
McKinsey & Company
|1
36. Emerging markets become an ever more important focus
%, $ billions
Global Medical Device Market1
Growth drivers in emerging markets
Developed markets
Emerging markets2
100% = 313
81
322
80
355
CAGR
2010-16
%
397
445
77
73
69
~3
31
~13
1 Households spending proportionally more
on healthcare as income rises
▪ Increasing wealth, average age, changing
lifestyle and prevalence of chronic diseases
▪ Increasing middle class, substantially
increasing discretionary income
2016
19
20
23
27
2008
10
12
14
2 Government HC spend increasing fast,
steadily rising as percent of spend
▪ Expanding insurance coverage
▪ Investment in delivery and medical
infrastructure
3 Physician education and training on the rise
Key to market penetration and development,
especially for medical products
What is happening in Africa?
1 Excludes surgical & injectable aesthetic devices & traditional wound care products; includes imaging service revenues
2 Includes Latin America, Africa, Carribean, Middle East, Asia (excluding Japan, New Zealand & Australia) & CEE
SOURCE: Health Research International 2010; Business Monitor International; McKinsey analysis
McKinsey & Company
|2
37. From the turn of the century Africa has started to generate
superior growth
Africa
Real GDP, CAGR, percent based on 2000 constant USD
Broad independence
and first military
coups
4.8
Communism, oil
shocks, and selfenrichment
The lost decade
4.5
3.8
3.1
1970 - 80
1980 - 90
▪
▪
▪
▪
▪
Most African
countries (32) gain
independence (e.g.,
Algeria, Nigeria)
Several military
coups (DRC, Ghana)
1964 – Mandela
sentenced
1967 – Egypt six-day
war
SOURCE: World Bank. McKinsey
▪
▪
▪
Last decade
+96%
4.9
1960 - 70
▪
AIDS, drought,
genocide, terrorism,
and Mandela
5.3
2.6
▪
World
5 more countries
gain independence
(e.g., Angola)
Oil price increases
from USD 3 to 38
1971 - 79 – military
coup by Amin in
Uganda
1974 – Rumble in
the Jungle
▪
▪
▪
▪
Oil price crashes
Reagan supporting
anti-communist
1983 – Islamic
revolution in Sudan
1984 – Ethiopia
famine
1985 – Military coup
in Nigeria
Carter push sanctions
on SA
2.6
2.8
2.5
1990 - 2000
▪
▪
▪
▪
▪
2000 - 10
AIDS epidemic
1993 – Battle of
Mogadishu in Somalia
1994 – Rwanda
genocide
1994 – Mandela wins
SA elections
1997 – U.S. firms
barred from doing
business with Sudan
(terrorism)
McKinsey & Company
|3
38.
39. Example – South Africa’s medical product market growth
expected to accelerate to 11% p.a.
South African medical product sales
R1 bn, 2008-11
Upgrade of hospitals nationally
($2-3bn over 3 years)
+11% p.a.
Phased introduction of national
health insurance (additional $2030bn into the system over next
15 yrs)
Rapidly growing middle income
segment / consuming class (1520% growth of middle income
groups by some estimates)
2.1
1.9
+3% p.a.
1.8
1.6
1.2 1.2
1.3
1.4 1.4
08 09 10 11
12 13 14 15 16
1 Nominal
SOURCE: BMI Pharmaceuticals & Healthcare Report, Q2 2012; McKinsey analysis
McKinsey & Company
| 5
40.
41.
42.
43. There are important access barriers
Limited
infrastructure/
capacity
Countries with poor
health-care
infrastructure (e.g.,
number of
physicians and
hospital beds)
Poor quality
Markets with
physicians lacking
awareness or skills
(e.g., to perform
advanced
procedures)
Restricted
funding and
reimbursement
Markets with
infrastructure and
quality, but restrictions on funding or
pricing (e.g.,
medical device
spending/ healthcare spending)
Broad access
Markets with good
infrastructure,
capacity/quality,
and favorable
funding or pricing
situation
Most Africa today
CEE today
Short-term
Rest of Europe today
Long-term
McKinsey & Company
|9
44.
45.
46. Collaboration for knowledge and technical transfer from large
global players is key– China example
Partnership
examples
Deal structure
Deal rationale
▪ Established joint
▪ GE: Leverage Shinva’s product portfolio and strengths
venture (GE 49% stake)
▪ Total JV investment
$25mn
▪ Philips acquired
Goldway in a deal worth
$46mn
in local manufacturing and procurement to develop and
promote mid-/low-end X-ray systems for the lower-end
healthcare market, which is a focus of the healthcare
reform
▪ Shinva: Obtain technology and quality support from
GE, and improve its brand image
▪ Philips: Leverage Goldway’s complementary patient
monitor portfolio, not only for the Chinese market, but
for export to other value-conscious, high-growth
markets
▪ Goldway: Take both brand and technology advantages
of Philips to improve marketing competitiveness and
provide more reliable and affordable products
▪ Medtronic acquired
▪ Medtronic: Expand beyond the high-end ortho market
15% stake of Weigao
with $221mn
▪ Established a JV for
orthopedic product line
(Medtronic 51% stake)
by leveraging Weigao’s mid- to low-end product
portfolio and sales network
▪ Weigao: Broaden business and improve R&D capability
to become a leading medical device company in Asia
SOURCE: Literature search; McKinsey analysis
McKinsey & Company
| 12
47. We see broader efforts in Africa emerging, but still lots of room to build
Recent partnerships in Africa
Philips and local partner PPC Ltd are
collaborating with the Federal Ministry of Health
with new Brilliance CT 16-slice scanner.
Phillips Healthcare partnered with the non-profit
organization Imaging the World (ITW) to
introduce the Philips CX50 Compact Xtreme
portable ultrasound system in local hospitals
▪ Siemens in partnered with Meditec Systems Ltd to
provide a complete solution to the Cancer Care
Centre in Nairobi, Kenya, which serves the
community of East and Central Africa
▪ Siemens and TOGA (ZA) have partnered on the
innovative TOGAtainer – a turnkey lab that can be
placed anywhere for decentralized lab services
SOURCE: McKinsey
McKinsey & Company
| 13
48. Support to establish local R&D hubs is another way
to transfer tech and improve access
Strategic initiatives
▪ Significant investments in R&D infrastructure
– Opened first global technology center in Gurgaon
– Conducts product development on all categories of
▪ Entered the Indian market through
$1.65bn acquisition of Howmedica, a
Pfizer subsidiary and leading producer of
orthopedic implants and instruments in 99
▪ Headquartered in Gurgaon, Haryana
▪ Has a 20% share in the joint replacements
market in India, but also sells surgical
equipment and hospital beds
SOURCE: Web search, press searches
operation
– Functions as a global talent hub for Stryker
operations throughout the world
– Plans to set up state-of-the-art operation theater at
the Gurgaon facility for interactive visual learning
with partners around the world
▪ Phase-wise product launch approach
– Went national after one year of launch in a region
(e.g., autologous blood transfusion product,
CONSTAVAC CBC II, the first such product in India)
▪ Market expansion through technology use
– Setting up telemedicine centers in India for
educational purposes through alliances with reputed
research institutes
McKinsey & Company
| 14
49.
50. The markets are very different and still shaping and growing
South Africa
45
Share of
total business
from small
player incl. locals
Global players
have 2-3%
shares
▪ Most products are still imported (e.g.,
▪
▪
Nigeria
▪
51
6 global players
including (incl. Mindray)
90% in Kenya), and global link through
local distributors
Some local production in South Africa but
focus mostly on distribution
The market still looking for broader
quality/price balance and service/tech.
support
Players like Toshiba and Mindray now
making strong in-roads
Local players should
▪ Start investing in selected
Kenya
▪
25
5 Global players
SOURCE: McKinsey analysis
▪
granular opportunities
Look for similar opportunities
already implemented ex-Africa
Early ventures/entrepreneurs
should actively seek investment
to capture selected growth
McKinsey & Company
| 16
51.
52. Euro-Africa Health Investment Conference
March 26-27, 2013
London, UK
Going beyond manufacturing:
the benefit of co-development and sustainable sourcing
FONDATION BDA
PHARMAFRICAN
53. WORLD MARKETS & OPPORTUNITIES
Annual sales growth
5 years (BCC Research 2010) :
Functional food
8.5 -10 %
Cosmetic products 15 %
WORLD SALE
OF HEALTH AND WELLNESS PRODCUTS
US$ 627.5 billions in 2010
US$ 772 billions in 2016
(Euromonitor international, 2011)
The cosmetics market is looking
diversify range. (BCC research 2010)
WORLD MARKT
OF NUTRACEUTICALS
US$ 243 billions in 2015
The antioxidants segment represents
approximately $ 500 million of revenue for
the component ingredients (Euromonitor 2011)
(Global Industry Analysts, 2010)
WORLD MARKET
OF BOTANICALS
> US$ 60 milliards
(CIC, Geneva)
WORLD MARKET
OF BOTANICAL DRUGS
US$ 32.9 billion In 2013
(BCC Research)
SUB-SAHARIAN AFRICA
25% of natural world
ressources, 0.01% OF WORLD
MARKET.
FONDATION BDA
to
PHARMAFRICAN
55. BDA & THE PLANT ACTION PROGRAM
AFRICA BASED PROGRAM
Plant Action Program
Entrepreneurship
and business
mentorship
PROCESSING CENTER
QA & QC
Botanicals
production &
processing
« ABS safe »
QUALITY LABORATORY
A new generation of agribusinessman
Responsible and sustainable sourcing of quality
controlled botanicals
TRIPLE BOTTOM LINE IMPACTS
ECONOMIC
SOCIAL
ENVIRONMENTAL
56. and GOVERNMENT together
focussing on economic governance's improvement
MULTILATERAL DONNORS
Ministry of Agriculture
Ministry of Environnement
Ministry of Health
Ministry of Labour
Ministry of Plan
MULTIPLE INTERNATIONAL
AW A R D S
Terre de Femmes Canada
International Biodiversity
Sustainable development Leader
Carole Robert Women of the Year
Canada-Africa Partnership
ABS model program | COP10
Model of Green Ecomony | Rio+20
FONDATION BDA
PHARMAFRICAN
57. PHARMAFRICAN
PharmAfrican is a young biopharma start-up, with a mission
to provide 3BL to shareholders (economic, social and
environmental) by developing and commercializing
inovative health ingredients » derived from highly value
added African plants, « botanicals », and responding to
the requirements and needs of B2B market:
of
the
natural
health
products
(Superfoods, cosmetics, nutraceuticals and functional
foods): PHARMAFRICAN INC. DIVISION
of the biopharmaceutic products («botanical drug»):
PHARMAFRICAN PHARMA DIVISION
PharmAfrican
works
in
partnership
with
Government, academic, industrial and social innovation
actors as part of a sustainable development hybrid
platform, to meet 3 levels of needs namely
economic, social and environmental, by promoting the
sharing of profits with a vision of development and
sustainable commitment.
58. Regulatory context
WHAT IS A
BOTANICAL DRUG ?
A botanical drug is intended for use as drug; a
drug that is prepared from a botanical substance.
FDA definition
Identification of active compounds not essential
Purification not required
FDA published on 6/9/06
Chemistry/Manufacturing and Control (CMC) is extended to raw material
Pre-clinical evaluations may be reduced
Same level of clinical efficacy/safety requirements as standard drugs
Utilization of the “historical” safety information to expedite early stage
testing and evaluation of botanical products
59. PharmAfrican Business Strategy
Botanical drugs
Pre-clinical
IND
Phase I
Phase II
Phase III
DIN
Market
Botanical drug
Deal with large pharmas looking for pipeline
FALLBACK POSITION
Pre-clinical
Clinical studies
Natural Products –
Supplements
Health Canada NHPD
FDA, Food supplement
Market accessible with large
marketing investment
60. OUR PLATFORM & INVESTMENT STRATEGY ?
Early stage R&D
in Africa
IMPACT
INVESTNG
?
Investment in
advanced R&D
Clinical studies
Scale up
Investment in
Manufacturing
( + cGMP) infrastructures)
Commercialisation and
marketing
African
universities ?
African
governments ?
POC
Specialized investment funds
Venture Capital funds
Industries
61. PARTNERING FOR IMPACT: JOINING FORCES TOWARD
ECONOMIC RETURN, SOCIAL INNOVATION AND GLOBAL ISSUES
Join the Team!
We are interested in talking to
Partners, Donors, Investors
Researchers and Innovators
We believe that companies that
implement a Stakeholder Strategy will
improve their returns to Shareholders
FONDATION BDA
PHARMAFRICAN